bioAffinity Technologies, Inc. Warrant
BIAFW
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 57
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
18.68% more ownership
Funds ownership: 2.56% [Q1] → 21.24% (+18.68%) [Q2]
0% more funds holding
Funds holding: 4 [Q1] → 4 (+0) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
32% less capital invested
Capital invested by funds: $65.2K [Q1] → $44.2K (-$21K) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for BIAFW